Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line ...

Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 billion to ...

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 ...

Eli Lilly & Co. is raising the list price for its obesity shot in the UK, as the pharma industry comes under pressure from US ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's ...

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.